Intranasal neuropeptide Y reverses anxiety and depressive-like behavior impaired by single prolonged stress PTSD model

L-Tetrahydropalmatine Ameliorates Development of Anxiety and Depression-Related Symptoms Induced by Single Prolonged Stress in Rats

“…It is characterized by intrusive recollections of the traumatic event, avoidance of reminders of the event, hyperarousal, and as being outside the realm of a normal human experience (Serova et al ., 2014). PTSD is often co-morbid with anxiety and major depression, as well as with substance abuse, sleep disturbances, and marked psychosocial and occupational impairment (Serova et al ., 2014).…”

“…It is characterized by intrusive recollections of the traumatic event, avoidance of reminders of the event, hyperarousal, and as being outside the realm of a normal human experience (Serova et al ., 2014). PTSD is often co-morbid with anxiety and major depression, as well as with substance abuse, sleep disturbances, and marked psychosocial and occupational impairment (Serova et al ., 2014). The symptoms of PTSD are believed to reflect trauma-induced changes that lead to long-term dysfunctional stress regulation and inappropriate adaptation of the hypothalamic-pituitary-adrenal (HPA) axis (George et al ., 2013a, 2013b).…”

Intranasal gene delivery for treating Parkinson’s disease: overcoming the blood–brain barrier

“…NPY also mediates behavioral resilience to traumatic stress [137], neuroinflammation, neurogenesis, and neuroprotection in various models of CNS injury [138]. Intranasal NPY has emerged as a strong candidate for treatment of PTSD [137], reducing behavioral signs of stress in an animal model of PTSD and blunting the accompanying increases in plasma corticosterone and ACTH [27,139,140]. Early, acute interventions with intranasal NPY may be useful in mitigating the development of PTSD, making a gene therapy unnecessary.…”

Endocrine Aspects of PTSD: Hypothalamic-Pituitary-Adrenal (HPA) Axis and Beyond

“…Intra-hippocampal injection of NPY immediately after PSS exposure could reduce the prevalence of extreme behavioral response, while injection of NPY receptor type 1 (NPY-Y1) antagonist produced the opposite effect (Cohen et al 2012). Serova et al showed a reversal of anxiety and depressive-like behaviors with an intranasal (less invasive) injection of NPY (anxiolytic properties) in the prolonged stress PTSD rodent model (Serova et al 2014). NPY administration represents a promising translational treatment, and the first proof-of-concept studies in PTSD are ongoing.…”